Patient survival and the combination of vitamin D and phosphorus binder in dialysis

Dialysis and Transplantation

Volumn 39, Issue 10, 2010, Pages 427-431

  Konta, Tsuneo ^a   Hoshikawa, Masato ^a   Takasaki, Satoshi ^a   Ichikawa, Kazunobu ^a   Mashima, Yusuke ^a   Takahashi, Toshiyuki ^b   Abiko, Hiroshi ^c   Masakane, Ikuto ^d   Matsunaga, Tomohito ^e   Suzuki, Masayuki ^f   Degawa, Noriyuki ^g   Kubota, Isao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b Okitama Public General Hospital   (Japan)

^c Nihonkai General Hospital   (Japan)

^d Yabuki Hospital   (Japan)

^e Eijinkai Hospital   (Japan)

^f Yamagata Prefectural Central Hospital   (Japan)

^g Yamagata City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM CARBONATE; FALECALCITRIOL; MISCELLANEOUS DRUGS AND AGENTS; PHOSPHATE BINDING AGENT; PHOSPHORUS; PHOSPHORUS BINDING AGENT; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIALYSIS; FEMALE; FOLLOW UP; HEART ARREST; HUMAN; JAPANESE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL;

EID: 78649280627     PISSN: 00902934     EISSN: 19326920     Source Type: Journal    
DOI: 10.1002/dat.20495     Document Type: Article

References (12)

1. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52: 519-530.
2. Noordzij M, Korevaar JC, Boeschoten EW, et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis. 2005; 46: 925-932.
3. Nakai S, Akiba T, Kazama J, et al. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial. 2008; 12: 49-54.
4. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
5. Naves-D'az M, Alvarez-Hernádez D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008; 74: 1070-1078.
6. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004; 19: 179-184.
7. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009; 20: 388-396.
8. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008; 12: 514-525.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: S1-201.
10. Dusso AS, Brown AJ., Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005; 289: F8-28.
11. Chertow GM, Burke SK, Raggi P., Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
12. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349: 446-456.